Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?
Information source: Stanford University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Depressive Disorder, Major
Intervention: venlafaxine XR (Drug); hydrocortisone (Drug)
Phase: N/A
Status: Active, not recruiting
Sponsored by: Stanford University Official(s) and/or principal investigator(s):
Charles DeBattista, Principal Investigator, Affiliation: Stanford University
Summary
The primary purpose of this study is to examine whether IV hydrocortisone can speed up the
time required for Venlafaxine XR to work.
Clinical Details
Official title: Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: To determine if treatment of major depression with hydrocortisone concurrent with starting venlafaxine XR speeds onset of antidepressant action.
Secondary outcome: To determine if hydrocortisone pre-treatment augments venlafaxine XR response.
Detailed description:
Participants will be treated with Venlafaxine XR for 6 weeks. The dose of Venlafaxine XR
will begin at 37. 5 mg/day and be gradually increased to a maximum of 225 mg/day. The dose
may be kept as low as 75 mg/day if necessary. Study doctor will be assessing mood to
determine if some patients respond more quickly than the several weeks often required for an
antidepressant to begin working. On the first day of treatment with Venlafaxine XR,
participant will be randomly assigned (similar to a flip of a coin) to receive
hydrocortisone 15 mg /day or placebo for two days. Placebo is an inactive substance, like a
sugar pill. This dose of hydrocortisone is less than a typical replacement dose for patients
who are not producing cortisol (hydrocortisone) naturally. The hydrocortisone is
administered intravenously (in a vein) over the course of 2 hours for two consecutive days.
Neither participant nor study doctor will know which treatment participant is receiving.
However, this information is available to study doctor if it is needed.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria::- outpatients at least 18 years of age
- current major depressive episode
- HDRS greater than or equal to 21
- good physical health Exclusion Criteria:- history of sensitivity, intolerance, or
non-response to venlafaxine
- history of sensitivity to hydrocortisone
- history of bipolar 1 illness
- meets DSM-IV criteria for a current or past psychotic disorder
- meets DSM-IV criteria for substance abuse or dependence in previous 6 months
- significant imminent suicide risk
- medical condition that would compromise participation in the study
- woman of child bearing potential not using adequate birth control in the opinion of
the investigator
Locations and Contacts
Stanford University School of Medicine, Stanford, California 94305, United States
Additional Information
Starting date: August 2002
Last updated: December 14, 2007
|
